Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00999401 · ClinicalTrials.gov registry record · Phase 1

A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

A Phase 1 study, sponsored by Cyclacel Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
103
Enrollment target

NCT00999401: Completed Phase 1 study, sponsored by Cyclacel Pharmaceuticals.

NCT00999401 is a Phase 1 study that has completed, run by Cyclacel Pharmaceuticals. The registered enrollment target is 103 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00999401, a Phase 1 study, has completed, sponsored by Cyclacel Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
103 participants
Enrollment target

Study Summary

A study of sequential administration of oral sapacitabine and oral Seliciclib in patients with advanced solid tumors.

Primary Outcome

MTD of both sapacitabine and seliciclib administered sequentially in advanced solid tumor patients

Interventions

  • DRUG sapacitabine and seliciclib

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2009-04
Est. Completion 2019-08-13
Phase Phase 1
Cyclacel Pharmaceuticals

13 total trials

What the finished NCT00999401 record still lists

NCT00999401 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% higher).

The record links to 0 conditions, and to 1 intervention - of which sapacitabine and seliciclib is the first listed.

NCT00999401 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00999401 about?

NCT00999401 is a clinical study titled "A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors". A study of sequential administration of oral sapacitabine and oral Seliciclib in patients with advanced solid tumors.

What is the current status of trial NCT00999401?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2009-04. Estimated completion is 2019-08-13.

What interventions are being tested in trial NCT00999401?

The interventions under investigation include: sapacitabine and seliciclib (DRUG).

Who is sponsoring clinical trial NCT00999401?

This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00999401's enrollment target sits among peer trials

103 541st of 2000 higher than 1,458 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04690348 · 103 participants · Phase 2

    Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

  • NCT05282277 · 103 participants · Phase 4

    Examining the Effects of Estradiol on Neural and Molecular Response to Reward

  • NCT05566769 · 103 participants · NA

    Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

  • NCT05834478 · 103 participants · Phase 3

    Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00999401, the US trial registry maintained by the National Library of Medicine. NCT00999401 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.